SciSparc Shares Surge 157% After NeuroThera Wins TSXV Approval for $9.46M CliniQuantum Deal
SPRC•SciSparc shares surged 157% after majority-owned NeuroThera Labs secured TSXV conditional approval to acquire a 54% stake in CliniQuantum Ltd. for $9.46 million. The deal enhances SciSparc’s pipeline in cannabinoid-based therapies by integrating CliniQuantum’s quantum simulation platform into clinical trial analytics.
1. Share Surge Following Regulatory Nod
SciSparc shares jumped 157% to close at $10.55 after its majority-owned subsidiary NeuroThera Labs received conditional approval from the TSX Venture Exchange to bid for a controlling interest in CliniQuantum Ltd.
2. Acquisition Details and Strategic Impact
NeuroThera Labs will acquire a 54% stake in CliniQuantum for about $9.459 million, securing access to quantum simulation platforms that analyze clinical trial data and may enhance precision in SciSparc’s cannabinoid-based drug development pipeline.
